摘要
经过多年的临床应用,盐酸普拉克索改善帕金森病运动、抑郁症状和预防运动并发症的疗效及其安全性已获得广泛认可。普拉克索缓释片与普拉克索速释片具有相同活性成分;普拉克索缓释片临床疗效和安全性与普拉克索速释片相当,且长期有效。缓释技术可保证每天1次给药,血药浓度平稳,24 h提供平稳持续的多巴胺能刺激,且不易漏服,极大地提高了依从性。超过80%的患者可由普拉克索速释片隔夜成功转换为普拉克索缓释片,且绝大多数无需剂量调整。普拉克索缓释片的上市,为帕金森病患者提供了优化治疗的新选择。文中对普拉克索缓释片的临床应用做一综述。
After years of clinical practice, the efficacy and safety of pramipexole dihydrochloride on controlling motor symptoms, improving Parkinson＇s disease（PD） depression, and preventing motor complications has been widely recognized. Compared with pramipexole IR（immediate release）, pramipexole SR（sustained-release） has the same active ingredient with comparable clinical efficacy and safety, providing long-term benefit. The sustained-release form ensure daily administration with steady plasma concentrations, providing continuous dopaminergic stimulation for 24 hours. Moreover, once daily administration leads to more convenience, resulting in better compliance. More than 80% patients could be successfully switched over night from pramipexole IR to pramipexole SR, without dosage adjustment for most patients. The launch of pramipexole SR provides a new optimized treatment option for PD patients. The clinical application of pramipexole SR was reviewed.
出处
《中国临床神经科学》
2015年第4期439-444,共6页
Chinese Journal of Clinical Neurosciences
关键词
帕金森病
普拉克索缓释片
治疗
Parkinson＇s disease
pramipexole sustained-release
treatment
